Edwards Lifesciences receives FDA approval for AUTUS pediatric pulmonary valve
Edwards Lifesciences announced that the U.S. Food and Drug Administration has approved its AUTUS pulmonary valve for use in children with congenital heart disease. The approval follows a pivotal clinical study that met the agency's safety and effectiveness criteria. The valve is designed to expand as a child grows, making it the first device with this capability. The clearance adds a pediatric product to Edwards' structural heart portfolio.
Why it matters
Edwards said the approval expands its structural‑heart offerings into the pediatric market, which could increase future sales. The product can now be marketed in the United States, opening a new revenue stream.
Key facts
- 1The FDA approved Edwards' AUTUS pulmonary valve for pediatric patients. tradingview.com
- 2A pivotal study met the FDA's safety and effectiveness endpoints. tradingview.com
- 3The valve can expand as the child grows, the first device with this feature. seekingalpha.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.